Standigm Signs Joint Research Agreement with National Cancer Center for Innovative Anticancer Drug Discovery

[Asia Economy Reporter Chunhee Lee] AI drug development company Standigm announced on the 16th that it has recently signed a joint research agreement with Dr. Hakkyun Kim of the National Cancer Center for the development of anticancer drug candidates.

Through this joint research, Standigm aims to accelerate the discovery of anticancer drug candidates targeting first-in-class drugs within its category.

Standigm utilizes its AI platform ‘Standigm BESTTM,’ which can design new molecular structures with optimal drug properties, to explore active compounds targeting specific targets, design new compounds, and select final evaluation candidates among them.

Dr. Hakkyun Kim applies his expertise in anticancer drug development research to evaluate the efficacy of compounds proposed by Standigm in vitro (cell-based) and in vivo (animal-based), as well as to elucidate the binding structures with the targets based on a self-developed target-specific model.

Yoon Sojung, CEO of Standigm, stated, “Based on our trust in the BEST platform, which can continuously generate drug candidates not limited to specific targets or indications, we are conducting joint research with major pharmaceutical companies and research institutions. We expect that by combining Standigm’s AI technology with Dr. Hakkyun Kim’s extensive experience and high-level expertise in anticancer drug research at the National Cancer Center, we can accelerate the development of innovative anticancer drugs.”

This content was produced with the assistance of AI translation services.